WVE: Wave Life Sciences Ltd. Stock

by  •  • Comments Off on WVE: Wave Life Sciences Ltd. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 595.52
Enterprise Value ($M) 403.05
Book Value ($M) 47.50
Book Value / Share 0.39
Price / Book 12.54
NCAV ($M) 7.93
NCAV / Share 0.06
Price / NCAV 75.12

Profitability (mra)
Return on Invested Capital (ROIC) -0.72
Return on Assets (ROA) -0.22
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.26
Current Ratio 1.26

Balance Sheet (mrq) ($M)
Current Assets 235.37
Assets 274.95
Liabilities 227.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 113.31
Operating Income -68.00
Net Income -57.51
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -19.43
Cash from Investing -1.11
Cash from Financing 132.53

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A 683 Capital Management, LLC 4.70 -6.67
02-14 13G/A Maverick Capital Ltd 6.90 19.02
02-13 13G/A Bb Biotech Ag 3.70 0.00
02-12 13G/A M28 Capital Management LP 6.00 24.90
02-07 13G/A Adage Capital Partners Gp, L.l.c. 5.03 8.34
02-06 13G/A Glaxosmithkline Plc 11.50 30.89

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-05 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ T
2023-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-22 97,538 492,475 19.81
2024-04-19 67,051 182,388 36.76
2024-04-18 71,004 262,711 27.03
2024-04-17 64,654 625,510 10.34

(click for more detail)

Similar Companies
VERA – Vera Therapeutics, Inc. VNDA – Vanda Pharmaceuticals Inc.
VRCA – Verrica Pharmaceuticals Inc. XENE – Xenon Pharmaceuticals Inc.
XNCR – Xencor, Inc.


Financial data and stock pages provided by
Fintel.io